Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

109 results about "Hcy homocysteine" patented technology

Homocysteine (HCY) Hyperhomocysteinemia is a medical condition characterized by elevated levels of the intermediate amino acid, homocysteine (HCY), in the blood. 1 HCY plays a key role in the remethylation/transmethylation and transsulfuration pathways that require folate, cobalamin, and pyridoxine as cofactors.

Ketone bodies and ketone body esters as blood lipid lowering agents

ActiveUS9211275B2Reduce serum cholesterol and/or triglyceride levelLowering of total serum cholesterol levelHydroxy compound active ingredientsMetabolism disorderChemistryNutritional composition
The subject disclosure provides compositions for reducing serum cholesterol and / or triglyceride levels in subjects. These compositions can comprise racemic β-hydroxybutyrate or D-β-hydroxybutyrate, optionally in the acid form, physiologically compatible salts of racemic β-hydroxybutyrate or D-β-hydroxybutyrate, esters of D-β-hydroxybutyrate, oligomers of D-β-hydroxybutyrate containing from 2 to 20 or more monomeric units in either linear or cyclic form, racemic 1,3 butandiol or R-1,3 butandiol alone and can be, optionally, administered in conjunction with a low fat diet to a subject. Alternatively, compositions comprising racemic β-hydroxybutyrate or D-β-hydroxybutyrate, optionally in the acid form, physiologically compatible salts of racemic β-hydroxybutyrate or D-β-hydroxybutyrate, esters of D-β-hydroxybutyrate, oligomers of D-β-hydroxybutyrate containing from 2 to 20 or more monomeric units in either linear or cyclic form, racemic 1,3 butandiol, R-1,3 butandiol or combinations thereof can be formulated as nutritional supplements (also referred to as nutritional compositions) or incorporated into therapeutic compositions containing a) anti-hypertensive agents; b) anti-inflammatory agents; c) glucose lowering agents; or d) anti-lipemic agents) which are administered to a subject, optionally in combination with a low fat diet, in order to cause a reduction or lowering of: serum cholesterol levels; triglyceride levels; serum glucose levels, serum homocysteine levels, inflammatory proteins (e.g., C reactive protein) and / or hypertension in treated subjects. Alternatively, compositions disclosed herein can be administered alone, or in combination with other therapeutic agents to prevent or reverse vascular disease.
Owner:OXFORD UNIV INNOVATION LTD +1

Reversible inhibitors of SAH hydrolase and uses thereof

1. The present invention provides compositions and methods for reversibly inhibiting S-adenosyl-L-homocysteine (SAH) hydrolase. The compounds of the present invention can be used as an anti-hemorrhagic viral infection agent, an immunosuppressant, a homocysteine lowering agent, or an anti-neoplasm agent. The compositions and methods of the present invention can be used for the prevention and treatment of hemorrhagic virus infection, autoimmune diseases, autograft rejection, neoplasm, hyperhomocysteineuria, cardiovascular disease, stroke, Alzheimer's disease, multiple sclerosis or diabetes. The compound of the present invention and / or used in the present invention has the formula (I):wherein Z is selected from the group consisting of carbon and nitrogen,R1 and R2 are the same or different, and are selected from the group consisting of hydrogen, hydroxy, alkyl, cycloalkyl, alkenyl, alkoxy, amino, aryl, heteroaryl, and halogen;R3 and R4 are the same or different and are selected from the group consisting of hydrogen, alkyl, acetyl, alkenyl, aryl, and heteroaryl;X is selected from the group consisting of oxygen, nitrogen, and sulfur; andY is selected from the group consisting of hydrogen, a C1-10 alkyl group, alkenyl, vinyl, aryl, and heteroaryl, provided that the compound is not (4-adenine-9-yl)-2-hydroxybutanoic acid.
Owner:NINGBO ZIYUAN PHARMA INC

Intra-intestinal nutrient emulsion for tumor patients

The invention belongs to the medicine field, and specifically relates to an intra-intestinal nutrient emulsion for tumor patients. The emulsion is characterized by comprises the following effective components: protein, fat, carbohydrate, total dietary fiber, green tea theine, taurine, L-carnitine, composite vitamins and mineral substances, and water. The protein is provided in an amino acid powder form, the formula of the amino acid powder is adjusted on the basis of 20 kinds of protein amino acids, wherein methionine is replaced by homocysteine, glutamine and glutamic acid are not added, the tryptophan content is low, and the content of branched chain amino acid reaches 35% or more; fat is provided in a saturated aliphatic acid or unsaturated fatty acid form, wherein in the unsaturated aliphatic acid the value of omega-6 / omega-3 is equal to 2-6 / 1; and the carbohydrate is provided in a form of glycerin, glucose, fructo-oligosaccharide or lentinan. Besides one prominent characteristic of the emulsion is that the emulsion is a high-fat and low-sugar type, and the ratio of sugar to fat is 1:1. The emulsion formula is adjusted according to the nutrient and metabolism requirements of tumor patients so as to develop an individualized intra-intestinal nutrient preparation for tumor patients, the preparation can provide balanced nutrients for tumor patients, effectively cures the malnutrition symptom, improves the life quality of patients, and can also be used to assist the tumor treatment.
Owner:湖北一半天制药有限公司

High-efficiency non-integrated human iPSC induction platform

The invention discloses a high-efficiency non-integrated human iPSC induction platform which comprises a composition, wherein the composition is used for inducing a human cell into iPSC, and the composition comprises a previous inducer and a later inducer; the previous inducer comprises the following active components: a transforming growth factor beta inhibitor, a glycogen synthetase kinase 3 inhibitor, a cAMP agonist, an S-adenosyl homocysteine hydrolase inhibitor and a p21 activated kinase inhibitor; and the later inducer comprises the following active components: the glycogen synthetase kinase 3 inhibitor, a selective ATP noncompetitive MEK inhibitor and the S-adenosyl homocysteine hydrolase inhibitor. The high-efficiency non-integrated human iPSC induction platform disclosed by the invention achieves the previous induction efficiency of the iPSC of 6.4% under the action of a previous inducer composition, can achieve the induction of a full culture of 20.8% through later induction culture or be used for totally further inducing a previous inductor clone into a human iPSC clone approaching to ESC and is far higher than the prior art in induction efficiency; in addition, the obtained iPSC is high in maturity, free of being inserted with an exogenous gene, is more approaching to the ESC in cell morphology and property and has the advantages of good stability and great high application value.
Owner:GUANGDONG HOSPITAL OF TRADITIONAL CHINESE MEDICINE

Cardiovascular and cerebrovascular and diabetes related four-high index composite quality control product and preparation method thereof

The invention relates to the technical field of medical diagnosis, and discloses a cardiovascular and cerebrovascular and diabetes related four-high index composite quality control product and a preparation method thereof. The composite quality control product comprises a matrix liquid, a reducing agent, bovine serum albumin, an anticoagulant, polyol, uric acid, homocysteine, glucose, low-densitylipoprotein cholesterol and a preservative. The composite quality control product which can be used for testing four cardiovascular and cerebrovascular and diabetic indexes of Glu, Hcy, UA and LDL-C at the same time can be prepared at a time, healthy human plasma is selected as a matrix liquid raw material, the components are basically consistent with those of serum after treatment, and the matrixeffect is reduced to the maximum extent; meanwhile, by matching with other components, the prepared four-high quality control product has good uniformity and stability, stable performance, long preservation time and simplicity and convenience in use, meanwhile, the accuracy of quality control during joint inspection is greatly improved, and a more accurate basis is provided for clinical diagnosisof cardiovascular and cerebrovascular diseases and diabetes related diseases.
Owner:SINOCARE

Dry homocysteine test card and application thereof

The invention relates to a dry homocysteine test card and application thereof, the dry homocysteine test card comprises a dissociation liquid R1 and dry chemical test paper, the dissociation liquid R1comprises a reducing agent, serine and a buffer solution; the dry chemical test paper comprises a supporting layer, a chromatographic membrane, an enzyme pad, a blood filtering layer, an enzyme circulation reaction layer, a diffusion layer and a plastic sheet; the chromatographic membrane, the enzyme pad, the blood filtering layer, the enzyme circulation reaction layer and the diffusion layer aresequentially overlapped on the supporting layer from bottom to top, the length of the chromatographic membrane is greater than that of the enzyme pad, the blood filtering layer, the enzyme circulation reaction layer and the diffusion layer, and the chromatographic membrane is fixed at one end close to the supporting layer and extends towards the other end of the supporting layer; a plastic sheetis arranged near one end, far away from the enzyme pad, of the supporting layer, a color developing region is arranged on the plastic sheet, the plastic sheet is positioned above the chromatographic membrane and is parallel to the chromatographic membrane, and the color developing region covers partial region of the chromatographic membrane. The test card has the advantages of being capable of detecting all homocysteine in human blood and high in sensitivity.
Owner:NINGBO MEDICAL SYSTEM BIOTECHNOLOGY CO LTD

Reversible inhibitors of S-adenosyl-L-homocysteine hydrolase and uses thereof

The present invention provides compositions and methods for reversibly inhibiting S-adenosyl-L-homocysteine (SAH) hydrolase. The compounds of the present invention can be used as an anti-hemorrhagic viral infection agent, an immunosuppressant, a homocysteine lowering agent, or an anti-neoplasm agent. The compositions and methods of the present invention can be used for the prevention and treatment of hemorrhagic virus infection, autoimmune diseases, autograft rejection, neoplasm, hyperhomocysteineuria, cardiovascular disease, stroke, Alzheimer's disease, multiple sclerosis or diabetes. The compound of the present invention and / or used in the present invention has the formula (I):wherein Z is selected from the group consisting of carbon and nitrogen,R1 and R2 are the same or different, and are selected from the group consisting of Hydrogen, hydroxy, alkyl, cycloalkyl, alkenyl, alkoxy, amino, aryl, heteroaryl, and halogen;R3 and R4 are the same or different and are selected from the group consisting of Hydrogen, alkyl, acetyl, alkenyl, aryl, and heteroaryl;X is selected from the group consisting of oxygen, nitrogen, and sulfur; andY is selected from the group consisting of hydrogen, a C1-10 alkyl group, alkenyl, vinyl, aryl, and heteroaryl, provided that the compound is not (4-adenine-9-yl)-2-hydroxybutanoic acid.
Owner:NINGBO ZIYUAN PHARMA INC

Folic acid sustained-release composition, sustained-release preparation and application thereof

The invention relates to the field of medicines, and particularly relates to a folic acid sustained-release composition, a sustained-release preparation and application thereof. The invention providesthe folic acid sustained-release preparation, which adopts a gastric retention technology and can prolong the retention time of a folic acid preparation in the stomach to 6 hours or above. The sustained-release preparation has lower administration frequency than a common-release preparation, and the administration frequency is reduced from 2-3 times per day to once per day, so that the preparation has a faster 5-methyltetrahydrofolic acid level increase rate than a common folic acid common-release preparation unexpectedly, and the rat animal model shows that the dosage of the 5-methyltetrahydrofolic acid level of the same body can be reduced by about 50% compared with the common-release preparation. The sustained-release preparation can be used for patients who need to take folic acid fora long time, such as megaloblastic anemia caused by folic acid deficiency, hyperhomocysteinemia caused by folic acid deficiency, cerebral apoplexy prevention and myocardial infarction caused by hyperhomocysteinemia, depression and anxiety induced by folic acid deficiency and the like.
Owner:北京斯利安药业有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products